2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 1931

Targeting Cartilage Aging As Osteoarthritis Therapeutics By Drug Repurposing

Biology and Pathology of Bone and Joint Poster II

9:00AM-11:00AM: Abstract Number: 2256

Temporal Increases in Side Effect Concerns of Osteoporosis Medications Among Women with Previous Fractures

Patient Outcomes, Preferences, and Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 1938

TGFB1 Governs Osteoblast Differentiation in Ankylosing Spondylitis Via Modulating BMP2

Biology and Pathology of Bone and Joint Poster II

9:00AM-11:00AM: Abstract Number: 2674

The Association between the Extent of Skin Thickness and Organ Involvement, Function and Quality of Life in Early Diffuse Cutaneous Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2667

The Association between Two Non-Invasive Methods for the Assessment of Severity of Gastrointestinal Involvement and Malnutrition in Systemic Sclerosis: Self-Reported Questionnaires and Nail Fold Video-Capillaroscopy

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2622

The Benefit of Vitamin D on SLE Disease Activity Is Largely Explained By Renal Activity

Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

9:00AM-11:00AM: Abstract Number: 1984

The Cervical Spine in Fibromyalgia Patients: Loss of Lordotic Curve Is Characteristic of Fibromyalgia and Can Assist in the Diagnosis

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

9:00AM-11:00AM: Abstract Number: 2282

The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Interim Report of Baseline Patient Characteristics and Treatment Choices

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2101

The Clinical Characteristics of IgG4 Related Disease in China: With 346 Cases Reported

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2666

The Clinical Utility of Flow-Mediated Dilation in Systemic Sclerosis Digital Ulcer Assessment

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2539

The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2102

The Difference between International Criteria for BD (ICBD) and the BD Criteria of International Study Group (ISG) in Our Behcet’s Disease (BD) Patients Who Fulfilled Japanese BD Criteria

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2496

The Disease Course in Daily Clinical Practice in Radiographic and Non-Radiographic Axial Spondyloarthritis Patients; One-Year Follow-up Results of National-Subgroup of a Worldwide Observational Cohort Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2513

The Effect of Alcohol on Disease Activity in Axial Spondyloarthritis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2367

The Effect of Glucocorticoids on Bone Mineral Density in Patients with Rheumatoid Arthritis: a Systematic Review and Meta-Analysis

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].